- Home
- LEGN vs CORT Comparison
LEGN vs CORT Comparison
Compare LEGN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGN | CORT |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 8.6B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LEGN | CORT |
|---|---|---|
| Price | $21.72 | $37.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $69.58 | ★ $119.20 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $909,045,000.00 | $741,172,000.00 |
| Revenue This Year | $68.52 | $23.96 |
| Revenue Next Year | $48.63 | $43.40 |
| P/E Ratio | ★ N/A | $39.84 |
| Revenue Growth | ★ 74.75 | 17.92 |
| 52 Week Low | $21.19 | $32.99 |
| 52 Week High | $45.30 | $117.33 |
Technical Indicators
Market Signals| Indicator | LEGN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 15.87 |
| Support Level | $21.35 | $32.99 |
| Resistance Level | $23.24 | $85.34 |
| Average True Range (ATR) | 0.68 | 4.07 |
| MACD | 0.19 | -5.34 |
| Stochastic Oscillator | 28.05 | 6.05 |
Price Performance
Historical ComparisonAbout LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.